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Abstract 
 
Introduction 
Non-small cell lung cancer (NSCLC) arises when epithelial cells lining the 
bronchial tubes undergo aberrant cell growth. The US Food and Drug Ad-
ministration (FDA) recently approved atezolizumab for the treatment of pa-
tients with metastatic NSCLC, whose disease progressed during or following 
platinum-based chemotherapy. Patients who progress following treatment 
for epidermal growth factor receptor (EGFR) or anaplastic lymphoma ki-
nase (ALK) genomic tumour aberrations may also receive atezolizumab. By 
inhibiting the programmed death ligand 1 (PD-L1), atezolizumab enables 
T-cell activation, restoring their ability to effectively detect and destroy tu-
mour cells.  
Methodology  
Published and grey literature were identified by searching the Cochrane Li-
brary, CRD Database, Embase, Ovid Medline, PubMed, Internet sites and 
contacting the manufacturer. Quality assessment was conducted to assess 
the risk of bias at the study level based on the EUnetHTA internal validity 
for randomized controlled trials. Furthermore, the magnitude of clinically 
meaningful benefit that can be expected from atezolizumab was evaluated 
based on, both the original and an adapted version of, the Magnitude of 
Clinical Benefit Scale (MCBS) developed by the European Society for Medi-
cal Oncology (ESMO). 
Results of the OAK trial 
Between 11 March 2014 and 29 April 2015, an intent-to-treat (ITT) popula-
tion of 425 patients was randomly assigned to receive either atezolizumab (n 
= 425) or docetaxel (n = 425). Atezolizumab increased the primary end-
point of overall survival (OS) in the ITT population by 4.2 months and dura-
tion of response (DOR) by 10.1 months, compared with docetaxel. Patients 
with higher PD-L1 expression derived the greatest improvement in median 
OS (+ 11.6 months) with atezolizumab, 20.5 months versus 8.9 months with 
docetaxel. Atezolizumab did not improve progression-free survival (PFS) or 
the proportion of patients with an objective response (OR) compared with 
docetaxel. While fewer patients had treatment-related AEs with atezoli-
zumab compared to docetaxel, clinically significant immune-related AEs 
were reported including pneumonitis, hepatitis, colitis and thyroid disease.  
Conclusion 
Overall, with the exception of those with EGFR mutations, atezolizumab in-
creases OS and DOR in previously treated NSCLC patients regardless of 
PD-L1 expression or histology, with a favourable safety profile compared to 
docetaxel. There is no evidence regarding quality of life, patient reported 
outcome measures or patient reported experience measures to determine 
whether atezolizumab provides clinically significant improvement in the 
symptoms or severity of NSCLC. Results from OAK hold limited external 
validity as participants are not entirely generalizable to clinical practice. 
Longer trials are needed that directly compare the safety and efficacy of ate-
zolizumab versus other immunotherapies such as nivolumab or pembroli-
zumab, or docetaxel in combination with nintedanib or ramucirumab.  
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to pre-defined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is atezolizumab? 
A0022 Who manufactures atezolizumab? 
A0007 What is the target population in this assessment? 
A0020 For which indications has atezolizumab received marketing authorisation? 
Health problem and current use 
A0002 What is NSCLC? 
A0004 What is the natural course of NSCLC? 
A0006 What are the consequences of NSCLC for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of NSCLC? 
A0003 What are the known risk factors for NSCLC? 
A0024 How is NSCLC currently diagnosed according to published guidelines and in practice? 
A0025 How is NSCLC currently managed according to published guidelines and in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of atezolizumab on mortality? 
D0005 How does atezolizumab affect symptoms and findings (severity, frequency) of NSCLC? 
D0006 How does atezolizumab affect progression (or recurrence) of NSCLC? 
D0011 What is the effect of atezolizumab on patients ̕ body functions? 
D0012 What is the effect of atezolizumab on generic health-related quality of life? 
D0013 What is the effect of atezolizumab on disease-specific quality of life? 
Safety 
C0008 How safe is atezolizumab in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying atezolizumab? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of atezolizumab? 
A0021 What is the reimbursement status of atezolizumab? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Atezolizumab/Tecentriq
®
/MPDL3280A 
 
B0001: What is atezolizumab? 
Up-regulation of the programmed death ligand 1 (PD-L1) in patients with 
haematological malignancies and solid tumours increases the propensity for 
cancer cells to evade immune surveillance. Atezolizumab, a monoclonal an-
tibody, is an immune checkpoint inhibitor. By inhibiting PD-L1, atezoli-
zumab enables T-cell activation, restoring their ability to effectively detect 
and destroy tumour cells [2].  
Atezolizumab is available in 1,200 mg/20 mL (60 mg/mL) single-use vials. It 
is administered as an intravenous infusion over 60 minutes, at a fixed dose 
of 1,200 mg, every three weeks until disease progression or unacceptable tox-
icity [2].  
 
A0022: Who manufactures atezolizumab? 
Genentech Inc, a subsidiary of F Hoffmann-La Roche Ltd 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Atezolizumab is indicated for previously treated non-small cell lung can-
cer (NSCLC) patients.  
 
 
 
4 Current regulatory status 
A0020: For which indications has atezolizumab received marketing authori-
sation? 
In May 2016, the US Food and Drug Administration (FDA) issued acceler-
ated approval of atezolizumab for the treatment of patients with locally ad-
vanced or metastatic urothelial carcinoma (MUC) with disease progression 
during or following platinum-based chemotherapy, or within 12 months of 
neoadjuvant or adjuvant treatment with platinum-based chemotherapy [2]. 
anti-PD-L1 antibody, 
immune checkpoint 
inhibitor 
 
1,200 mg IV over 60 
minutes every 3 weeks 
 
previously treated 
NSCLC patients 
FDA: licensed for locally 
advanced or MUC in 
May 2016 
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In October 2016, the US FDA approved atezolizumab for the treatment of 
patients with metastatic NSCLC whose disease progressed during or follow-
ing platinum-based chemotherapy. Patients with epidermal growth factor 
receptor (EGRF) or anaplastic lymphoma kinase (ALK) genomic tumour 
aberrations who progress following prior therapy for these aberrations may 
also receive atezolizumab [2].  
Atezolizumab does not currently have marketing authorisation in Europe for 
any indication.  
 
 
 
5 Burden of disease 
A0002: What is NSCLC? 
NSCLC is the most common epithelial lung cancer and accounts for approx-
imately 80–85% of all lung cancers. The most common histological types of 
NSCLC are squamous (25–30%), adenocarcinoma (40%) and large cell car-
cinoma (10–15%). Squamous cell, also known as epidermoid, carcinoma is 
typically centrally located, characterized by keratin, more common in males 
and tobacco smokers, and has a 10% survival rate at 5 years [3, 4]. Adenocar-
cinoma and large cell carcinoma are typically peripherally located and have 
survival rates of approximately 5–6% at 5 years. A subset of approximately 
7–35% of NSCLC patients has driver gene alterations in EGRF or ALK. 
NSCLC tumours express the immune checkpoint PD-L1 that negatively 
regulates T-cell proliferation and induces cell death in tumour-specific T-
cells. PD-L1 expression ranges from 23–27% in non-squamous NSCLC and 
from 19–56% in squamous NSCLC [5].  
 
A0004: What is the natural course of NSCLC? 
Lung cancer typically arises when epithelial cells lining the bronchial tubes 
undergo aberrant cell growth. To facilitate treatment, lung cancer is staged 
from I through IV based on tumour size, and presence or absence of lymph 
node involvement and metastases (TNM). Stage I lung cancer is <3 cm and 
localized to one lobe; stage II has spread to other parts of the lung or lymph 
nodes; stage III may be large or spread to lymph nodes between the lungs; 
and stage IV has metastasized to the adjacent lung, brain, liver or bones [3, 
6].  
A0006: What are the consequences of NSCLC for the society? 
Lung cancer is the second most commonly diagnosed cancer. While the im-
plementation of smoking cessation programs, , and multidisciplinary treat-
ments have reduced the incidence and mortality, 52–58% of lung cancer pa-
tients present with advanced-stage disease when curative treatment is no 
longer feasible. Patient prognosis is poor due to the high rate of relapse and 
early formation of micro-metastases [7]. 
 
 
FDA: licensed for 
metastatic NSCLC in 
October 2016 
EMA: currently not 
authorised 
NSCLC accounts for 80–
85% of all lung cancers 
EGFR + ALK alterations 
in 7–35% of NSCLC 
patients 
staged I–IV by 
invasiveness 
 
metastasize to bone, 
liver, brain, lymph nodes 
52–58% present with 
advanced cancer; 
relapse and metastasize 
early 
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A0023: How many people belong to the target population? 
Lung cancer is the leading cause of cancer-related death in men and the sec-
ond in women worldwide. The age standardized incidence rate for the Euro-
pean Standard Population was 56.9 per 100,000 persons per year in 2013. In 
Austria, 2,894 men and 1,822 women were newly diagnosed with lung cancer 
in 2014; and 3,908 men and 2,450 women died due to lung cancer (47.3 per 
100,000 persons per year) [8]. Approximately 6.5% of people will be diag-
nosed with lung cancer during their lifetime and at least a third of newly di-
agnosed patients have distant metastases. The average age at diagnosis is 
approximately 70 years [4].  
 
A0005: What are the symptoms and the burden of NSCLC? 
Many lung cancers are not symptomatic until they have spread. Symptoms 
of NSCLC include incessant cough, bloody sputum, chest pain, wheezing or 
hoarseness, weight loss or loss of appetite, shortness of breath, fatigue, and 
recurrent bronchitis or pneumonia. Lung cancer may metastasize to bone, 
brain, liver or lymph nodes causing pain, headaches, improper balance, sei-
zures, jaundice or lumps near the body’s surface [3].  
 
A0003: What are the known risk factors for NSCLC? 
The risk of lung cancer increases with age, tobacco use, radiation exposure, 
air pollution, and occupational exposure to asbestos, arsenic, chromium be-
ryllium, nickel and other agents. The risk of developing lung cancer is ten-
fold higher in smokers compared to lifetime non-smokers. Smoking cessa-
tion decreases precancerous lesions and reduces the risk of developing lung 
cancer [3].  
 
A0024: How is NSCLC currently diagnosed according to published guide-
lines and in practice? 
While some lung cancers may be found through screening, most are identi-
fied when they become symptomatic. Following a clinical history and physi-
cal exam, a chest x-ray may be done to identify any abnormal areas in the 
lungs. A CT scan may show the size, shape and location of any lung tumours 
or enlarged lymph nodes, and guide a needle biopsy if a suspected area is 
identified. Lung cancer is diagnosed by examining cells derived through bi-
opsy or sputum sampling for the presence of cancer cells. Immunohisto-
chemical (IHC) and molecular tests may be conducted to identify specific 
changes in the gene expression of cancer cells to target first-line treatment 
for NSCLC patients with genetic aberrations in EGRF or ALK genes. PD-
L1 expression on tumour cells and tumour-infiltrating immune cells can be 
assessed using the Ventana PD-L1 (SP142) IHC assay [6]. 
 
 
 
4,716 Austrians were 
diagnosed with NSCLC 
in 2014 
average age at diagnosis 
~70 years 
NSCLC symptoms: 
cough, chest pain, 
weight loss, shortness of 
breath 
main risk factor: 
smoking 
diagnosis: x-ray, CT and 
biopsy 
PD-L1 status: IHC assay 
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6 Current treatment 
A0025: How is NSCLC currently managed according to published guide-
lines and in practice? 
Depending on the tumour stage, histology, and the patient’s overall health, 
surgery, radiation therapy and/or platinum-based chemotherapy may be 
used alone or in combination to treat NSCLC.  
 Stage I and II NSCLC patients typically undergo surgery to remove 
the cancer. Stage II patients may benefit from postoperative adjuvant 
chemotherapy or radiation therapy.  
 Patients with stage I or II cancers that are not surgical candidates, 
due to co-morbidities or limited lung function, may undergo local ra-
diation therapy.  
 Stage III NSCLC patients are highly heterogeneous and may undergo 
a combination of treatments depending on the extent and localization 
of disease as well as prior treatments.  
 Patients with stage IV disease are treated with systemic therapy or a 
symptom-based palliative approach.  
In appropriately selected patients, chemotherapy, molecularly targeted ther-
apy, and/or immunotherapy may extend survival.  
 Docetaxel is the preferred chemotherapy agent for squamous NSCLC 
and for non-squamous NSCLC patients previously treated with 
pemetrexed.  
 Ramucirumab may be used concurrently, when treating with docet-
axel, for patients with a good performance status [6].  
 The molecular characterization of tumour tissue in NSCLC patients 
may guide treatment in those with metastatic disease or relapse fol-
lowing primary therapy [6]. NSCLC patients with driver gene altera-
tions in EGFR or ALK may benefit from tyrosine kinase inhibitors 
such as erlotinib, gefitinib, afatinib or crizotinib. Afatinib is indicat-
ed as second-line treatment for patients with squamous NSCLC 
based on improved OS and PFS compared with erlotinib [9]. Patients 
with advanced disease without EGFR or ALK mutations may receive 
antibody therapy with bevacizumab targeted against the vascular en-
dothelial growth factor (VEGF).  
 Pembrolizumab and nivolumab block PD-L on T lymphocytes and 
are used as second-line therapies for advanced NSCLC. Nivolumab is 
used for the treatment of patients with advanced squamous NSCLC 
and non-squamous NSCLC who experience progression on or after 
standard platinum-chemotherapy regardless of PD-L1 protein ex-
pression. Pembrolizumab is used in previously treated advanced 
NSCLC that expresses PD-L1 [6]. 
 
 
 
treatment by stage: 
surgery, radiation 
therapy, chemotherapy 
 
 
 
 
Docetaxel: preferred 
chemotherapy 
 
targeted therapies 
 
immunotherapies 
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7 Evidence 
A literature search was conducted on 13 March 2017 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “Atezolizumab”, “Tecentriq”, “MPDL3280A”, “NSCLC” 
and “non-small cell lung cancer”. The manufacturer was also contacted and 
submitted nine references (seven of which had already been identified by 
systematic literature search). A manual search yielded two FDA approval 
documents [2, 10], six clinical guidance documents [3, 5-7, 11], two statisti-
cal documents [4, 8], and a cost editorial [12]. Ongoing trials information 
was found on clinicaltrials.gov. Overall, 105 references were identified.  
A phase II and three phase III studies contributed to the evidence regarding 
efficacy and safety of atezolizumab for pre-treated NSCLC patients.  
Included in this reported are:  
 OAK, phase III [13-15] 
 POPLAR, phase II [16-18] 
 FIR, phase II [19], and 
 BIRCH, phase II [20, 21] 
To assess the risk of bias at the study level the assessment of the methodo-
logical quality of the evidence was conducted based on the EUnetHTA in-
ternal validity for RCTs [22, 23]. Evidence was assessed based on the ade-
quate generation of the randomisation sequence, allocation concealment, 
blinding of patient and treating physician, selective outcome reporting and 
other aspects that may increase the risk of bias. Study quality details are re-
ported in Table 5 of the Appendix. 
To evaluate the magnitude of clinically meaningful benefit that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS) was used [24]. Additionally, an adapted version (due to perceived 
limitations) of the ESMO-MCBS was applied [25]. Details of the magnitude 
of the clinically meaningful benefit scale are reported in Table 3. 
 
 
7.1 Clinical efficacy and safety – Phase III studies 
OAK (NCT02008227) [13] is an open-label, randomized, phase III multicen-
tre study involving 1,225 NSCLC patients who progressed following plati-
num-based chemotherapy. The primary analysis population comprised the 
first 850 randomized patients; the remaining 375 patients enrolled contrib-
uted to the final safety population of 1,225 patients.  
systematic literature 
search in 5 databases: 92 
hits 
included: 4 studies 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
magnitude of clinically 
meaningful benefit 
assessed based on 
ESMO-MCBS 
 
OAK: atezolizumab 
versus docetaxel in 1,225 
previously treated 
NSCLC patients;  
ITT = 850 
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Inclusion criteria were stage IIIB or IV squamous or non-squamous NSCLC, 
age ≥18 year, with measurable disease per Response Evaluation Criteria in 
Solid Tumours (RECIST; version 1.1) and Eastern Cooperative Oncology 
Group (ECOG) performance status of 0 or 1. Patients with EGFR or ALK 
aberrations must have received previous tyrosine kinase inhibitor therapy. 
Patients with a history of autoimmune disease and those previously treated 
with docetaxel, CD137 agonists, anti-CTLA4, PD-L- or PD-L1-targeted 
therapies were excluded. Tumour specimens were evaluated prospectively 
for PD-L1 expression on tumour cells (TC) and tumour-infiltrating immune 
cells (IC) using the Ventana PD-L1 (SP142) IHC assay. Eligible patients 
were stratified by PD-L1 expression status, number of prior chemotherapy 
regimens and histology.  
Patients were randomized 1:1 to receive either atezolizumab 1,200 mg or 
docetaxel 75 mg/m
2
 intravenously over 60 minutes every three weeks until 
unacceptable toxicity or disease progression. Approximately 609 (21% of) 
atezolizumab recipients and 578 (2% of) docetaxel recipients had a treat-
ment duration longer than 12 months. Median treatment duration was 3.4 
months with atezolizumab and 2.1 months with docetaxel.  
The primary endpoint was overall survival (OS) compared between treat-
ment groups within the intention-to-treat (ITT) and the PD-L1 TC1/2/3 or 
IC1/2/3 populations. TC1/2/3 or IC1/2/3 was defined as PD-L1 expression 
on ≥1% of TC or IC; TC2/3 or IC2/3 was defined as PD-L1 expression on 
5% of cells; TC3 was defined as PD-L1 expression on ≥ 50% of tumour cells 
and IC3 as ≥10% of tumour-infiltrating immune cells; and TC0 as PD-L1 
expression on ≤1% of tumour infiltrating immune cells [13]. Secondary 
endpoints included investigator-assessed objective response rates (ORR), 
progression-free survival (PFS), duration of response (DOR) and safety. 
Tumours were assessed every 6 weeks for the first 36 weeks and every 9 
weeks thereafter. Patients were followed-up for survival while receiving 
treatment and every 3 months following treatment discontinuation. The me-
dian follow-up was 21 months at the time of primary analysis.  
The ITT population (n = 850) had a median age of 64 years (range 33 to 85), 
61% were male, 70% were Caucasian, 75% had received one prior platinum-
based chemotherapy and 25% had received two prior therapies. Baseline 
ECOG performance status was 0 (37%) or 1 (63%). Approximately 74% of 
patients had non-squamous NSCLC, 10% had EGFR mutations, 0.2% had 
ALK aberrations, and 82% were current or previous smokers. Of the 850 pa-
tients, 16% were classified as having high PD-L1 expression (TC3 and IC3). 
Detailed patient characteristics including inclusion and exclusion criteria 
are reported in Table 4 of the appendix while study quality is reported in 
Table 5 of the appendix. Clinical efficacy data are presented in Table 1; ad-
verse events (AEs) are presented in Table 2.  
 
7.1.1 Clinical efficacy 
D0001: What is the expected beneficial effect of atezolizumab on mortality? 
Atezolizumab improved OS, regardless of histology or PD-L1 expression in 
both the ITT and TC1/2/3 or IC1/2/3 populations compared with docetaxel. 
At primary analysis, median follow-up of 21 months, 271 (64% of) atezoli-
zumab recipients and 298 (70% of) docetaxel recipients had died. Median 
OS in the ITT population was 13.8 months for atezolizumab versus 9.6 
 
 
 
ITT stratified by PD-L1 
expression, prior 
chemotherapy and 
histology 
 
 
 
 
Atezolizumab 1,200 mg 
vs docetaxel 75 mg/m2 
IV every 3 weeks 
endpoints: OS in ITT and 
PD-L1 expressing 
populations, PFS, ORR, 
DOR and safety 
ITT: 75% non-
squamous, 82% 
smokers, 75% had one 
prior chemotherapy, 
16% high PD-L1 
expression  
median OS in the ITT:  
13.8 months for 
atezolizumab vs 9.6 
months for docetaxel 
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months for docetaxel (HR 0.73 [95% CI 0.62–0.87]; p = 0.0003). In the 
TC1/2/3/ or IC1/2/3 population, 151 (63% of 241) atezolizumab recipients 
and 149 (67% of 222) docetaxel recipients had died. Median OS was 15.7 
months with atezolizumab versus 10.3 months with docetaxel (HR 0.74 [95% 
CI 0.58–0.93]; p = 0.0102) in the TC1/2/3/ or IC1/2/3 population [13].  
Atezolizumab recipients with high PD-L1 expression (TC3 or IC3) derived 
the greatest benefit, with a median OS of 20.5 months versus 8.9 months in 
docetaxel recipients (HR 0.41 [95% CI 0.27–0.64; p < 0.0001]). Patients in 
the low or undetectable subgroup TC0 and IC0 also had improved survival 
with atezolizumab (median OS 12.6 months versus 8.9 months; HR 0.75 
[95% CI 0.59–0.96]; p = 0.0215). Compared with docetaxel (n = 110), ate-
zolizumab (n = 112) improved median OS in both squamous (n = 313, HR 
0.73 [95% CI 0.54–0.98]; p = 0.0383) and non-squamous (docetaxel n = 315, 
atezolizumab n = 313; HR 0.73 [95%CI 0.60–0.89]; p = 0.0015) NSCLC pa-
tients [13, 15]. HRs of OS were also in favour of atezolizumab in the prede-
fined subgroups of patients treated with CNS metastases and never smokers 
(HR 0.54 [95% CI 0.31–0.94] and HR 0.71, [95% CI 0.47–1.08], respectively). 
In contrast, no statistically significant difference in OS was found between 
groups in patients with EGFR mutations. The median OS for patients with 
EGFR mutation was 10.5 months in the atezolizumab group vs 16.2 months 
in the docetaxel group (HR 1.24 [95% CI 0.71–2.18]) [13]. 
 
D0006: How does atezolizumab affect progression (or recurrence) of 
NSCLC? 
No statistically significant difference in PFS was found between treatment 
groups in the ITT or the TC1/2/3 or IC1/2/3 populations. At primary analy-
sis, 380 (89% of) atezolizumab recipients and 375 (88% of) docetaxel recipi-
ents achieved PFS. Median PFS was 2.8 months for atezolizumab versus 4.0 
months for docetaxel (HR 0.95 [95% CI 0.82–1.10]; p = 0.49) [13, 14]. Sub-
population analysis showed that the TC3 or IC3 group demonstrated a 
greater PFS with atezolizumab than docetaxel (HR 0.63 [95% CI 0.43–0.91]; 
p = 0.0123) [13]. 
 
D0005: How does atezolizumab affect symptoms and findings (severity, fre-
quency) of NSCLC? 
No statistically significant difference in ORR was found between treatment 
groups in the ITT or the TC1/2/3 or IC1/2/3 populations. However, atezoli-
zumab recipients in the ITT population derived longer DOR than docetaxel 
recipients (16.3 months versus 6.2 months). Responses are ongoing in 30 
(52%) of 58 atezolizumab recipients and 10 (18%) of 57 docetaxel recipients 
[13]. According to subgroup analysis, the proportion of patients with an ob-
jective response (OR) improved with atezolizumab versus docetaxel in the 
TC3 or IC3 group (22/72 patients versus 7/65 patients); lowest for TC0 and 
IC0 patients (14/180 patients versus 21/199 patients). DOR improvement 
with atezolizumab versus docetaxel was similar in all PD-L1 expression 
subgroups [13].  
 
 
 
median OS in the PD-L1 
expressing population:  
20.5 months for 
atezolizumab vs 8.9 
months for docetaxel 
OS benefit consistent 
across subgroups: 
histology, CNS 
metastases, never 
smokers 
 
NO benefit for patients 
with EGFR mutation 
PFS similar between 
treatment groups 
 
ORR similar between 
treatment groups 
 
 
 
median DOR in the ITT: 
16.3 months for 
atezolizumab vs 6.2 
months for docetaxel 
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D0011: What is the effect of atezolizumab on patients’ body functions? 
Atezolizumab may affect body functions by causing immune-mediated ad-
verse events including pneumonitis, hepatitis, colitis, hypothyroidism, hy-
perthyroidism, pneumonia and infections. The use of therapeutic proteins 
may result in immunogenicity. Among 135 patients in OAK, 73 (54%) tested 
positive for treatment-induced anti-therapeutic antibodies (ATA) at one or 
more post-dose time points. The presence of ATAs did not have a clinically 
significant impact on pharmacokinetics, safety or efficacy [2].  
 
D0012: What is the effect of atezolizumab on generic health-related quality 
of life? 
No evidence was found regarding the effect of atezolizumab on generic 
health-related quality of life (QoL).  
 
D0013: What is the effect of atezolizumab on disease-specific quality of life? 
No evidence was found regarding the effect of atezolizumab on disease-
specific QoL.  
 
 
Table 1: Efficacy results of OAK [13-15] 
Descriptive statistics 
and estimate varia-
bility 
Treatment group Atezolizumab  
 
Docetaxel  
 
Number of subjects  n = 425 n = 425 
Median OS, months (95% CI) 
ITT 
TC1/2/3 or IC1/2/3 
TC3 or IC3 
TC0 and IC0 
Squamous 
Non-squamous 
CNS metastases 
Never smokers 
EGFR mutation positive 
 
13.8 (11.8–15.7) 
15.7 (12.6–18.0); n = 241 
20.5 (17.5–NE) 
12.6 (9.6–15.2) 
8.9 (7.4–12.8) 
15.6 (13.3–17.6) 
20.1 (NR) 
16.3 (NR) 
10.5 (NR) 
 
9.6 (8.6–11.2) 
10.3 (8.8–12.0); n = 222 
8.9 (5.6–11.6) 
8.9 (7.7–11.5) 
7.7 (6.3–8.9) 
11.2 (9.3–12.6) 
11.9 (NR) 
12.6 (NR) 
16.2 (NR) 
PFS events (%) 
ITT 
TC1/2/3 or IC1/2/3 
 
380 (89) 
216/241 (90) 
 
375 (88) 
193/222 (87) 
Median PFS, months (95% CI) 
ITT 
TC1/2/3 or IC1/2/3 
TC3 or IC3 
 
2.8 (2.6–3.0) 
2.8 (2.6–4.0) 
4.2 (2.9-7.0) 
 
4.0 (3.3–4.2) 
4.1 (2.9–4.3) 
3.3 (2.7-4.2) 
ORR (%) 
OR ITT  
OR TC1/2/3 or IC1/2/3 
 
58 (14) 
43/241 (18) 
 
57 (13)  
36/222 (16) 
Median DOR, months (95% CI) 
ITT 
TC1/2/3 or IC1/2/3 
 
16.3 (10.0–NE) 
16.0 (9.7–NE) 
 
6.2 (4.9–7.6) 
6.2 (4.9–9.2) 
 
 
 
immune-mediated AEs, 
immunogenicity 
 
no evidence: generic 
health-related QoL 
 
no evidence: disease-
specific QoL 
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Effect estimate per com-
parison 
 
Comparison groups Atezolizumab vs docetaxel 
Study endpoint Patient population HR (95% CI), p-value 
OS 
(primary endpoint) 
 
 
 
ITT (n = 850) 
TC1/2/3 or CI1/2/3 (n = 463) 
TC3 or IC3 (n = 137) 
TC0 and IC0 (n = 379) 
Squamous (n = 222) 
Non-squamous (n = 628) 
CNS metastases (n = 85) 
Never smokers (n = 156) 
EGFR mutation positive (n = 85) 
 
 
0.73 (0.62–0.87), p = 0.0003 
0.74 (0.58–0.93), p = 0.0102 
0.41 (0.27–0.64), p < 0.0001 
0.75 (0.59–0.96), p = 0.0215 
0.73 (0.54–0.98), p = 0.0383 
0.73 (0.60–0.89), p = 0.0015 
0.54 (0.31–0.94), p = NR 
0.71 (0.47–1.08), p = NR 
1.24 (0.71–2.18), p = NR 
PFS events 
 
 
ITT 
TC1/2/3 or CI1/2/3 
 
0.95 (0.82–1.10), p = 0.49 
0.91 (0.74–1.12), p = 0.38 
Median PFS  
ITT 
TC3 or IC3 
 
0.95 (0.82–1.10), p = 0.4928 
0.63 (0.43-0.91); p=0.0123 
DOR  
ITT 
TC1/2/3 or CI1/2/3 
 
0.34 (0.21–0.55), p < 0.0001 
0.38 (0.22–0.65), p = 0.0003 
Abbreviations: CI = confidence interval; CNS = central nervous systems, DOR = duration of response; HR = hazard ratio; IC = tumour 
infiltrating immune cells; ITT = intention-to-treat; NE = not evaluable, NR = not reported; ORR = objective response rate: OS = overall 
survival; PFS = progression-free survival; TC = tumour cells; vs = versus 
 
 
7.1.2 Safety 
 
C0008: How safe is atezolizumab in relation to the comparator(s)? 
One grade 5 AE was reported in the docetaxel group. Grade 3 or 4 AEs were 
reported in 227 (37%) of 609 atezolizumab recipients and 310 (54%) of 578 
patients treated with docetaxel; out of those 15% (90/609) in the atezoli-
zumab group and 43% in the docetaxel group were reported due to treat-
ment-related grade ≥3 AEs. The most common atezolizumab-related AEs, of 
any grade, were fatigue (27%), decreased appetite (24%), cough (23%), as-
thenia (19%), and dyspnoea (19%). Pruritus and musculoskeletal pain were 
more common in atezolizumab recipients than patients receiving docetaxel. 
Approximately 8% (46/609) atezolizumab recipients and 19% (108/578) 
docetaxel recipients discontinued treatment due to AEs and one treatment-
related death occurred in the docetaxel group due to a respiratory tract in-
fection [13].  
 
C0002: Are the harms related to dosage or frequency of applying 
atezolizumab? 
NSCLC patients receive a fixed dose of 1,200 mg atezolizumab intravenous-
ly over 60 minutes every three weeks. If the first infusion is tolerated, 
subsequent infusions may be delivered over 30 minutes. Severe infusion 
reactions have occurred in 1.6% (16/1027) patients with NSCLC. It is 
necessary to interrupt or slow the rate of infusion in patients with mild or 
most common AEs: 
fatigue, decreased 
appetite, cough, 
asthenia, dyspnoea and 
nausea 
 
infusion reactions: 1.6% 
of patients; interrupt or 
infuse slowly 
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moderate infusion reactions and discontinue use in patients with grade ≥3 
infusion reactions [2].  
Study participants receive a median treatment duration of 3.4 months (range 
0–26) with atezolizumab and median treatment duration of 21 months 
(range 0–23) with docetaxel. Approximately 40% atezolizumab patients were 
treated with a median treatment duration beyond progression of three cycles 
(range 1–34). AEs leading to dose modifications, delay or interruption 
occurred in 25% (152/609) and 36% (210/578) of patients in the 
atezolizumab and docetaxel group, respectively [13]. 
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of atezolizumab? 
Study participants had a median age of 63 years and a good performance sta-
tus (ECOG performance 0 or 1). Patients with a history of autoimmune dis-
ease or compromised immunity were excluded from the study [13]. While 
OS benefit was observed across age subgroups (<65, 65–74, 75–84), there 
were too few patients to estimate OS and PFS for those ≥85 years [15]. Clin-
ical specificity of older patients and those with comorbidities, co-
medications, reduced functional reserve, and immunosenescence may affect 
the efficacy and/or toxicity of immune-checkpoint inhibitors in this popula-
tion [11]. 
Atezolizumab may impair fertility and cause fetal harm resulting in in-
creased rates of abortion or stillbirth. Females are advised to use effective 
contraception during treatment and refrain from breast feeding for at least 5 
months following the last dose of atezolizumab [2].  
median treatment 
duration: 3.4 months 
(range 0–26 months) 
 
susceptibles: elderly, 
immune compromised, 
comorbid, reduced 
functional status 
atezolizumab may cause 
fetal harm 
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Table 2: Most frequent treatment-related adverse events of OAK [13] 
 
Adverse Event (according  
to CTCAE version 4.0) 
 
Atezolizumab  
(n = 609) 
Docetaxel  
(n = 578) 
All AEs any grade, n (%) 390 (64) 496 (86) 
AEs in ≥10% of patients  Any Grade 
n (%) 
Grade 3 or 4 
n (%) 
Any Grade 
n (%) 
Grade 3 or 4 
n (%) 
Fatigue 163 (27) 17 (3) 205 (36) 23 (4) 
Decreased appetite 143 (24) 2 (<0.5) 136 (24) 9 (2) 
Cough 141 (23) 2 (<0.5) 105 (18) 1 (<0.5) 
Nausea 108 (18) 4 (1) 131 (23) 2 (<0.5) 
Diarrhoea 94 (15) 4 (1) 141 (24) 11 (2) 
Asthenia 116 (19) 8 (1) 114 (20) 13 (2) 
Dyspnoea 118 (19) 15 (3) 112 (19) 14 (2) 
Anaemia 70 (12) 14 (2) 136 (24) 33 (6) 
Alopecia  3 (1) 0 (0) 202 (35) 1 (<0.5) 
Constipation 107 (18) 2 (<0.5) 82 (14) 1 (<0.5) 
Pyrexia 108 (18) 1 (<0.5) 76 (13) 1 (<0.5) 
Peripheral edema 54 (9) 1 (<0.5) 82 (14) 3 (1) 
Vomiting 74 (12) 2 (<0.5) 62 (11) 4 (1) 
Arthralgia 73 (12) 3 (1) 58 (10) 1 (<0.5) 
Myalgia 39 (6) 1 (<0.5) 91 (16) 4 (1) 
Back pain 67 (11) 7 (1) 42 (7) 4 (1) 
Neutropenia 10 (2) 3 (1) 90 (16) 75 (13) 
Peripheral neuropathy 24 (4) 0 (0) 65 (11) 7 (1) 
Musculoskeletal pain 64 (11) 4 (1) 25 (4) 1 (<0.5) 
Stomatitis 19 (3) 1 (<0.5) 63 (11) 11 (2) 
Dysgeusia 18 (3) 0 (0) 58 (10) 0 (0) 
Febrile neutropenia  1 (<1) 1 (<0.5) 62 (11) 62 (11) 
Abbreviations: AE = adverse event; CTCAE = common terminology for cancer adverse events 
 
 
7.2 Clinical effectiveness and safety –  
further studies 
POPLAR (NCT01903993) is an open-label, randomized, phase II study 
comparing the safety and efficacy of atezolizumab versus docetaxel in 287 
NSCLC patients who progressed on post-platinum chemotherapy [16]. Eli-
gible patients were stratified by PD-L1 expression status, number of prior 
chemotherapy regimens and histology, and randomized to atezolizumab 
1,200 mg (n = 144) or docetaxel 75 mg/m
2
 (n = 143) intravenously every 
three weeks until unacceptable toxicity or disease progression.  
POPLAR: atezolizumab 
1,200 mg vs docetaxel 75 
mg/m2 IV every 3 weeks; 
ITT = 287  
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OS in the ITT population was 12.6 months for atezolizumab versus 9.7 
months for docetaxel (HR 0.73, [95%CI 0.53–0.99]; p = 0.04). Improved OS 
was associated with increasing PD-L1 expression (TC3 or IC3 HR 0.49 [95% 
CI 0.22–1.07]; p = 0.068; TC2/3 or IC2/3 HR 0.54 [95% CI 0.33–0.89]; p = 
0.014; TC1/2/3 or IC1/2/3 HR 0.59 [95%CI 0.40–0.85]; p = 0.005; TC0 and 
IC0 HR 1.04 [95%CI 0.62–1.75]; p = 0.871). Patients with pre-existing im-
munity, defined by high T-effector-interferon--associated gene expression, 
had improved OS with atezolizumab. Approximately 8% of atezolizumab re-
cipients and 22% of docetaxel recipients discontinued use due to AEs. Re-
sults suggest that atezolizumab significantly improved OS compared to 
docetaxel in previously treated NSCLC. Improvement in OS was correlated 
to PD-L1 expression and may be predictive for atezolizumab benefit [16]. 
PFS and ORR did not reflect the OS benefit seen with atezolizumab versus 
docetaxel suggesting that OS benefit may extend beyond disease progression 
by RECIST v1.1 [17, 18].  
Two other non-randomized, single-arm, phase II studies, FIR 
(NCT01846416) [19] and BIRCH (NCT02031458) [20, 21], assessed the safe-
ty and efficacy of PD-L1-positive patients with locally advanced or metastat-
ic NSCLC. Atezolizumab improved OS in both chemotherapy-naïve and 
previously treated NSCLC. Higher PD-L1 expression (TC3 or IC3) was as-
sociated with higher ORR based on RECIST v1.1 [19-21].   
 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of atezolizumab? 
Currently, no price estimates are available for Austria. Atezolizumab costs 
approximately US $12,500 per month [12]. Median treatment duration of 
approximately 3.4 months with atezolizumab would cost US$ 42,500.  
 
 
9 Ongoing research 
Several studies evaluating the use of atezolizumab as monotherapy or in 
combination as second-line therapy for NSCLC are ongoing. A search of 
clinicaltrials.gov using search terms “atezolizumab” and “NSCLC” yielded 
36 registered studies (nine phase III, 14 phase II, and 13 phase I studies). 
Most studies were industry-sponsored or conducted in collaboration with 
industry.  
Selected ongoing phase III and II studies for pre-treated NSCLC patients:  
 NCT02813785: open-label, randomized, controlled trial to evalu-
ate the efficacy and safety of atezolizumab compared with docet-
axel in NSCLC after failure with platinum-based chemotherapy. 
Estimated primary completion date is May 2019.  
OS ITT: 12.6 for 
atezolizumab versus 9.7 
for docetaxel 
 
OS benefit correlated 
with increasing  
PD-L1 expression 
 
FIR and BIRCH: 
atezolizumab improved 
ORR in chemo-naïve and 
previously treated 
NSCLC; benefit 
correlated PD-L1 
expression 
estimate: US $12,500; 
no price estimates 
available for Austria 
36 registered trials; 8 
industry-sponsored 
ongoing phase III 
studies  
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 NCT02486718: open-label, randomized study to evaluate efficacy 
and safety of atezolizumab with best supportive care following ad-
juvant cisplatin-based chemotherapy in patients with completely 
resected stage IB-IIIA NSCLC. Estimated primary completion 
date is September 2026.  
 NCT03014648: evaluate the efficacy of PD-l1 inhibition with ate-
zolizumab in advanced squamous and non-squamous NSCLC pa-
tients previously treated with anti-PD-1 therapy with either 
nivolumab or pembrolizumab in three cohorts, progressive disease, 
stable disease and partial to complete response followed by progres-
sive disease. Estimated primary completion date is October 2022.  
 NCT02630186: evaluate safety and anti-tumour effects of the com-
bination of rociletinib and atezolizumab in patients with advanced 
or metastatic EGFR-mutant NSCLC. Estimated primary comple-
tion date is December 2016.  
 NCT02716038: evaluate the effectiveness of nab-paclitaxel + car-
boplatin + atezolizumab for treating NSCLC. Estimated primary 
completion date is April 2020.  
 NCT03023423: comparative effectiveness of daratumumab in com-
bination with atezolizumab versus atezolizumab alone in patients 
with previously treated NSCLC. Estimated primary completion 
date is July 2018.  
 NCT02495636: evaluate the effects of combining atezolizumab and 
CDX-1401. Estimated primary completion date is July 2017. 
 NCT02174172: evaluate the safety and tolerability of atezolizumab 
in combination with other immune-modulating therapies in the 
treatment of advanced or metastatic NSCLC. Estimated primary 
completion date is February 2019.  
 
 
 
10 Discussion 
In October 2016, the US FDA approved atezolizumab, 1,200 mg IV adminis-
tered every 3 weeks, for the treatment of patients with metastatic NSCLC, 
whose disease progressed during or following platinum-based chemothera-
py. Patients with driver gene alterations in EGFR or ALK must have disease 
progression on prior therapy to receive atezolizumab. The approval was 
based on two international, randomized, open-label trials, OAK (phase III) 
and POPLAR (phase II) [2]. Atezolizumab does not currently have market 
authorization in Europe.  
FDA approved 
atezolizumab for NSCLC 
in October 2016;  
not approved in Europe 
Atezolizumab (Tecentriq
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OAK, a randomized, open-label, phase III study evaluated the comparative 
efficacy and safety of atezolizumab versus docetaxel in a total of 1,225 
NSCLC patients after failure with platinum-based chemotherapy. Com-
pared with docetaxel, atezolizumab increased OS in the ITT population by 
4.2 months and DOR by 10.1 months. Patients with high PD-L1 expression 
(TC3 and IC3) derived the greatest improvement in median OS with atezoli-
zumab, 20.5 months versus 8.9 months with docetaxel (+ 11.6 months). 
Nevertheless, the efficacy results showed that PD-L1-targeted therapy with 
atezolizumab resulted in improved OS compared with docetaxel in previous-
ly treated NSCLC regardless of PD-L1 expression or histology, and response 
was durable except for patients with EGFR mutations.  
Compared with docetaxel, atezolizumab did not improve PFS or the propor-
tion of patients with an OR. Investigators suggest that the discordance be-
tween PFS and OS may be due to an initial increase in tumour volume from 
increased immune filtration, delayed anti-tumour activity, or anti-tumour 
immune activation beyond progression that may be sustained with contin-
ued treatment. Post-progression prolongation of survival has been previous-
ly noted for EGFR inhibitor therapies and OAK results imply this effect 
may also occur with atezolizumab treatment [26]. While fewer patients had 
treatment-related AEs with atezolizumab compared to docetaxel, clinically 
significant immune-related AEs were reported including pneumonitis, hepa-
titis, colitis and thyroid disease [13].  
The clinical efficacy results of OAK are consistent with phase II data from 
POPLAR where atezolizumab increased the OS of previously-treated 
NSCLC patients by 2.9 months compared with docetaxel [16]. These results 
also correspond with phase II data from FIR and BIRCH demonstrating a 
correlation between increased improvement in OS with increasing PD-L1 
expression [16, 19-21].  
Several methodological limitations of the OAK study compromise internal 
validity. While patients were randomized to atezolizumab or docetaxel by 
permuted-block via a centralized randomization system, allocation conceal-
ment was not maintained and may influence how participants were assigned 
to a given group. Internal validity is compromised in an open-label study, 
where patients, treating physicians and outcome assessors are aware of 
which treatment a patient received introducing potential for bias in the es-
timated effect of an intervention. However, an independent data monitoring 
committee reviewed safety data.  
Given the non-curative setting of atezolizumab and the statistically signifi-
cant primary endpoint OS we applied Form 2a of the ESMO-MCBS in or-
der to assess whether atezolizumab satisfies the criteria for a “meaningful 
clinical benefit” (score 4 or 5). Both the original as well as the adapted ver-
sion of the MCBS were applied [24, 25]. The application of the ESMO-
MCBS to the OAK study resulted in a grade 4 and 3 in the original and the 
adapted version of the ESMO-MCBS, respectively. Therefore, atezolizumab 
only leads to a meaningful clinical benefit in the original scale, but not in 
the adapted framework. This difference occurs due to the use of the point es-
timate of the HR and the higher implication of toxicities in the adapted 
ESMO-MCBS. 
OAK: atezolizumab 
improved OS and DOR, 
and reduced AEs 
compared to docetaxel 
 
atezolizumab improved 
OS regardless of PD-L1 
expression or histology, 
with the exception of 
EGFR-positive patients 
atezolizumab did not 
improve PFS or ORR 
compared to docetaxel 
 
 
atezolizumab resulted in 
immune-related AEs 
 
OAK results consistent 
with phase II data from 
POPLAR, FIR, BIRCH 
 
high risk of bias: open-
label, unmasked 
allocation; industry 
funded 
 
ESMO-MCBS: 
grade A in the original 
scale 
grade C in the adapted 
framework 
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Results of the OAK study hold some limitations. Subgroup analyses were 
not powered for formal efficacy comparisons and should be interpreted with 
caution; the EGFR mutation-positive population may warrant further study. 
Generalizability of results may be limited. While OAK study participants 
were a median age of 63 with good performance status, this may compromise 
external validity as the average age at diagnosis for NSCLC is 70 years [4]. 
Clinical specificity of older patients and those with comorbidities, higher 
ECOG scores, and immunosenescence may affect the efficacy and or toxicity 
of immunotherapies in this population [11]. While evaluating median OS, 
PFS, ORR, and discontinuation data are useful outcomes in clinical trials, 
no evidence was reported regarding generic health-related or disease-specific 
QoL. Patient reported outcomes (PROMs) and patient reported experiences 
(PREMs) would be useful in determining whether atezolizumab provides 
adequate clinical benefit in terms of improving the symptoms and severity 
of NSCLC. While three immunotherapeutics, nivolumab, pembrolizumab, 
and atezolizumab, are approved for NSCLC based on statistically and clini-
cally significant improvement in OS compared to docetaxel, docetaxel com-
bination standards (nintedanib or ramucirumab) may prove a better com-
parator [27]. Follow-up may have been insufficient to identify all potential 
AEs or to assess the long-term effects of developing treatment-induced 
ATAs.  
The cost of atezolizumab is approximately US $12,500 per month and is not 
yet known for Europe. Median treatment duration of approximately 3.4 
months with atezolizumab would cost US$ 42,500. There are approximately 
4,716 new cases of lung cancer being diagnosed each year in Austria, and at 
least one third of newly diagnosed patients having distant metastases.  
Overall, OAK is the first phase III randomized study to report that com-
pared to docetaxel, PD-L1 targeted immunotherapy with atezolizumab in-
creases OS and DOR in previously treated NSCLC patients regardless of 
PD-L1 expression or histology with a favourable safety profile compared to 
docetaxel. Although, OS is improved, there is no evidence regarding QoL, 
PROMs or PREMs to determine whether atezolizumab provides clinically 
significant improvement in symptoms or severity of NSCLC. Results from 
OAK hold limited external validity as participants are not entirely general-
izable to clinical practice. While several studies are ongoing, longer trials are 
needed that directly compare the safety and efficacy of atezolizumab versus 
other immunotherapies such as nivolumab or pembrolizumab, or docetaxel 
in combination with nintedanib or ramucirumab.  
 
 
 
 
 
subgroup analysis 
underpowered 
 
 
 
poor external validity: 
clinical specificity in 
susceptibles may affect 
efficacy or toxicity 
 
insufficient follow-up to 
determine effects of 
developing treatment-
induced ATAs 
 
US $12,500/month 
US $42,500/3.4 months 
PROMs and PREMs data 
may inform value of 
atezolizumab in 
improving symptoms 
and severity 
 
 
improved OS and DOR 
with a favourable safety 
profile 
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Table 3: Benefit assessment based on original ESMO-MCBS and adapted benefit assessment based on adapted ESMO-MCBS [34, 35] 
Abbreviations: AJ = Adjustments, FM = final adjusted magnitude of clinical benefit grade, HR = hazard ratio, m = months, MG = median gain, ND = no difference, NSCLC = non-small lung cancer, OS = overall survival, 
PE = primary endpoint, PM = preliminary magnitude of clinical benefit grade, QoL = quality of life 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint 
of interest, and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the 
exact same score resulting from the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically fa-
vours drugs with a higher degree of uncertainty (broad CI). Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and out-
comes that lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, therefore, a reason for confounding. Hence, we report the adjust-
ments separately. 
                                                             
1
 One level upgrade because <10% grade ≥3 adverse events. 
ESMO-
MCBS 
Active sub-
stance 
Indication Intention PE Form MG standard 
treatment 
Efficacy Safety 
AJ FM 
MG months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
adapted 
ESMO-
MCBS 
atezolizumab pre-treated 
NSCLC 
Not 
curative 
OS 2a ≤1 year +4.2 
0.73 
0.62–0.87 
HR >0.65–0.70 OR Gain 
1.5–2.4 months 
2 
-28% grade  
3–4 AEs (+1)1 
- +1 3 
ESMO-
MCBS atezolizumab 
pre-treated 
NSCLC 
Not 
curative OS 2a ≤1 year +4.2 
0.73 
0.62–0.87 
HR ≤0.65 AND Gain ≥3 
months 
4 - - - 4 
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Table 4: Characteristics of the OAK trial 
Title: Atezolizumab versus docetaxel in patients with previously treated non-small cell lung cancer [13] 
Study identifier NCT02008227, GO28915, EudraCT  2013-003331-30, OAK 
Design Open-label, multicentre (31 countries, 194 centres), randomized controlled phase III study 
Duration of main phase: Recruited 850 patients to ITT March 11, 2014 to Nov 28, 
2014 
Enrolled final 375 patients by April 29, 2015 completing 
safety population. 
At primary analysis (July 7, 2016), median follow-up was 
21 months; 596 patients had died. 
Duration of Run-in phase: Not applicable 
Duration of Extension phase: Not applicable 
Hypothesis 
Superiority 
The study was designed to evaluate the efficacy and safety of atezolizumab compared with docet-
axel in patients with locally advanced or metastatic NSCLC after failure with platinum-containing 
chemotherapy.   
Funding F. Hoffmann-La Roche Ltd, Genentech Inc. 
Treatments groups 
 
Atezolizumab 
(n=425 ITT; n=609 safety popula-
tion) 
1,200 mg IV over 60 minutes every 3 weeks until unac-
ceptable toxicity or disease progression 
Docetaxel  
(n=425 ITT; n=578 safety popula-
tion) 
75 mg/m2 IV over 60 minutes every 3 weeks until unac-
ceptable toxicity or disease progression 
Endpoints and definitions 
 
Overall survival OS Time from randomization to death  
Compared between treatment groups within the ITT and 
the PD-L1 TC1/2/3 or IC1/2/3 populations (4.5 years) 
Progression-free 
survival  PFS 
Time from randomization to first occurrence of RECIST 
v1.1-defined disease progression or all-cause death 
Overall response rate determined using RECIST (v1.1) (1 
year) 
Objective re-
sponse rate 
ORR Overall response rate evaluated with RECIST (v1.1) (1 year) 
Duration of re-
sponse DOR 
Time from first occurrence of objective response to time of 
RECIST v1.1-defined disease progression or all-cause death 
Duration of response evaluated with RECIST (v1.1) (1 year) 
Safety, adverse 
events AE 
Incidence of adverse events according to NCICTAE (v4.0) 
(up to 1 year) 
Database lock Last verified November 2016 
Results and Analysis  
 
Analysis description Primary Analysis 
ITT: OS planned when 70% of ITT patients had died. July 7, 2016, median FU: 21 months; 569 pa-
tients had died (271 atezolizumab, 298 docetaxel recipients). OS, PFS, DOR compared between 
treatment groups; stratified log-rank test at two-sided significance. Median OS by Kaplan-Meier; 
95% CI by Brookmeyer-Cowley. HR by Cox regression. Pre-specified analyses of consistency of 
treatment effect according to baseline characteristics and PD-L1 expression subgroups. ORR by 
Clopper-Pearson; Cochran-Mantel-Haenszel.  
Safety population: included final 375 enrolled for a total population of 1225 patients. 
The funder provided study drugs, was involved in study design, data collection, analysis, interpreta-
tion, report writing and provided approval to submit publication. Safety monitored by independent 
committee. 
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Title: Atezolizumab versus docetaxel in patients with previously treated non-small cell lung cancer [13] 
Study identifier NCT02008227, GO28915, EudraCT  2013-003331-30, OAK 
Analysis population   
Inclusion 
 Adult patients ≥18 years of age 
 LA or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC 
 FFPE tumour specimens 
 Disease progression during or following prior platinum-
containing regimen for LA, unresectable/inoperable/metastatic 
NSCLC or recurrence within 6 months of platinum-based chemo-
therapy 
 Measurable disease, as defined by RECIST v1.1 
 ECOG performance status of 0 or 1 
 
Exclusion 
 Active or untreated CNS metastases 
 Malignancies other than NSCLC within 5 years prior to randomi-
zation, except those treated with expected curative outcome or 
negligible risk of metastasis or death 
 History of autoimmune disease, idiopathic pulmonary fibrosis, 
drug-induced or active pneumonitis, or organizing pneumonia 
 Active hepatitis B or C 
 Prior treatment with docetaxel, CD137 agonists, anti-CTLA4, or 
anti-PD-1 pathway-targeting therapeutics  
 
Characteristics 
 
 
Atezolizumab 
(n=425) 
 
Docetaxel 
(n=425) 
 
Overall ITT  
(n=850) 
Median age (range), 
years 
Ages ≥65 years, (%) 
63 (33-82) 
 
190 (45) 
64 (34-85) 
 
207 (49) 
64 (33-85) 
 
397 (47) 
Male sex, (%) 261 (61) 259 (61) 520 (61) 
Race (%) 
Caucasian 
Asian 
Black 
Other 
Unknown 
 
302 (71) 
85 (20) 
5 (1) 
13 (3) 
20 (5) 
 
296 (70) 
95 (22) 
11 (3) 
9 (2) 
14 (3) 
 
598 (70) 
180 (21) 
16 (2) 
22 (3) 
34 (4) 
ECOG performance 
status (%) 
0 
1 
 
 
155 (36) 
270 (64) 
 
 
160 (38) 
265 (62) 
 
 
315 (37) 
535 (63) 
Tobacco history 
(%) 
Never 
Current 
Previous 
 
84 (20) 
59 (14) 
282 (66) 
 
72 (17) 
67 (16) 
286 (67) 
 
156 (18) 
126 (15) 
568 (67) 
EGFR mutation (%) 
Positive 
Negative 
Unknown 
 
42 (10) 
318 (75) 
65 (15) 
 
43 (10) 
310 (73) 
72 (17) 
 
85 (10) 
628 (74) 
137 (16) 
ALK translocation 
Positive 
Negative 
Unknown 
 
2 (<1) 
223 (52) 
200 (47) 
 
0 (0) 
201 (47) 
224 (53) 
 
2 (<1) 
424 (50) 
424 (50) 
Histology 
Non-squamous 
Squamous 
 
313 (74) 
112 (26) 
 
315 (74) 
110 (26) 
 
628 (74) 
222 (26) 
PD-L1 subgroups 
TC3 or IC3 
TC2/3 or IC2/3 
TC1/2/3 or IC1/2/3 
TC0 and IC0 
 
72 (17) 
129 (30) 
241 (57) 
180 (42) 
 
65 (15) 
136 (32) 
222 (52) 
199 (47) 
 
137 (16) 
265 (31) 
463 (54) 
379 (45) 
Previous LA or met-
astatic therapies 
(%) 
1 
2 
 
 
 
320 (75) 
105 (25) 
 
 
 
320 (75) 
105 (25) 
 
 
 
640 (75) 
210 (25) 
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Title: Atezolizumab versus docetaxel in patients with previously treated non-small cell lung cancer [13] 
Study identifier NCT02008227, GO28915, EudraCT  2013-003331-30, OAK 
 Initially designed to enrol 850 patients, increased to 1300 patients to power for OS compari-
son in patients with high PD-L1 expression; final enrolment was 1225 patients 
- Subgroup analyses were not powered for formal efficacy comparison; interpret with caution 
- Patients were stratified by PD-L1 expression, number of previous chemotherapies, and his-
tology 
- TC1/2/3 or IC1/2/3 was defined as PD-L1 expression on 1% of TC or IC; TC2/3 or IC2/3 as PD-L1 
expression on 5% of cells; TC3 as PD-L1 expression on 50% or more TCs and IC3 as 10% or 
more on IC; TC0 and IC0 as PD-L1 expression on less than1% of TC or IC 
-Permuted block-randomization via interactive voice or web response system; open-label; in-
vestigator-assessed PFS 
- ITT population comprises first 850 patients randomized (1:1) to atezolizumab (1200 mg IV) 
or docetaxel (75 mg/m2) every 3 weeks; safety population comprises 609 atezolizumab recip-
ients and 578 docetaxel recipients 
- Of 425 assigned atezolizumab, 298 discontinued (270 died, 26 withdrew, 2 LFUP); of 425 as-
signed docetaxel, 347 discontinued (297 died, 48 withdrew, 2 LFUP)  
Abbreviations: ALK = anaplastic lymphoma kinase; CNS = central nervous system; CTLA4 = cytotoxic T-lymphocyte-associated protein 4; 
ECOG = Eastern Cooperative Oncology Group; EGFR = epidermal growth factor receptor; FFPE = representative formalin-fixed paraffin-
embedded; FU = follow-up; ITT = intent-to-treat; IV = intravenous; KRAS = V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; LA = 
locally advanced; LFUP = lost to follow-up; NCICTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events; 
NSCLC = non-small cell lung cancer; ORR = objective response rate; OS = overall survival; PD-L1 =programmed death ligand-1; PFS: 
progression-free survival; RECIST = Response Evaluation Criteria in Solid Tumours 
 
Table 5: risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomized controlled trials) 
[22] 
Criteria for judging risk of bias  risk of bias 
Adequate generation of randomisation sequence: permuted block-randomized (block size of 
8) to assign 1:1 ratio atezolizumab vs docetaxel via centralised interactive web-based and 
voice-based randomisation system 
no 
Adequate allocation concealment: trial centres enrolled the patients and allocation was 
specified as unmasked 
yes 
Blinding 
Patient: open-label, patients unmasked yes 
Treating Physician: open-label, unmasked yes 
Outcome assessment: open-label, investigator-assessed PFS yes 
Selective outcome reporting unlikely: outcomes reported as specified in protocol; with-
drawals and drop-outs reported 
no 
No other aspects which increase the risk of bias: industry funded the study, provided study 
drugs, and was involved in study design, data collection, analysis, interpretation, writing of 
the report and provided approval to submit for publication.  
high 
Risk of bias – study level high 
Abbreviations: PFS = progression-free survival 
